Morphic Medical, Inc.
GIDYL
OTC PK
| 03/31/2021 | 12/31/2020 | 09/30/2020 | 06/30/2020 | 03/31/2020 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -4.93% | -- | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.13% | -- | -- | -- | -- |
| Operating Income | 16.13% | -- | -- | -- | -- |
| Income Before Tax | 40.19% | -- | -- | -- | -- |
| Income Tax Expenses | -56.82% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 40.23% | -- | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.23% | -- | -- | -- | -- |
| EBIT | 16.13% | -- | -- | -- | -- |
| EBITDA | 16.20% | -- | -- | -- | -- |
| EPS Basic | 100.00% | -- | -- | -- | -- |
| Normalized Basic EPS | 82.05% | -- | -- | -- | -- |
| EPS Diluted | 100.00% | -- | -- | -- | -- |
| Normalized Diluted EPS | 82.05% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 195.70% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 195.70% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
